Skip to search formSkip to main contentSkip to account menu

ARC 1779

Known as: ARC-1779, ARC1779 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
quency counts and percentages. Continuous variables were summarized using one or more of the following: mean, standard deviation… 
Highly Cited
2012
Highly Cited
2012
Blockade of hyperactive von Willebrand factor (VWF) by ARC1779 blunted the platelet drop induced by desmopressin in patients with… 
Highly Cited
2011
Highly Cited
2011
Congenital thrombotic thrombocytopenic purpura (TTP) is a very rare but potentially life-threatening disorder. This phase I/II… 
Highly Cited
2011
Highly Cited
2011
Thrombotic thrombocytopenic purpura (TTP) can cause severe organ damage due to enhanced platelet aggregation by ultra-large von… 
Review
2010
Review
2010
Platelet inhibitors are the mainstay treatment for patients with vascular diseases. The current ‘gold standard’ antiplatelet… 
Highly Cited
2010
Highly Cited
2010
Desmopressin aggravates thrombocytopenia in type 2B von Willebrand disease (VWF type 2B) by release of large and hyper-adhesive… 
Highly Cited
2009
Highly Cited
2009
Summary.  Background: von Willebrand factor (VWF) has a role in both hemostasis and thrombosis. Platelets adhere to damaged… 
Highly Cited
2009
Highly Cited
2009
BACKGROUND: Plasma exchange is the main therapy for thrombotic thrombocytopenic purpura (TTP). No treatments other than plasma… 
Review
2008
Review
2008
von Willebrand factor (VWF) plays a pivotal role in platelet adhesion and aggregation at sites of high shear rates (eg, in… 
Highly Cited
2007
Highly Cited
2007
Background— ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor…